Stock 6535 LUMOSA THERAPEUTICS CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Lumosa Therapeutics Co., Ltd.

Equities

6535

TW0006535008

Biotechnology & Medical Research

End-of-day quote Taipei Exchange
Other stock markets
 06:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
172 TWD -.--% Intraday chart for Lumosa Therapeutics Co., Ltd. +3.30% +151.83%
Apr. 24 Lumosa Therapeutics Co., Ltd. cancelled the transaction announced on May 31, 2023 CI
Apr. 07 GenEditBio Limited announced that it has received funding from Lumosa Therapeutics Co., Ltd., Qiming Weichuang Venture Capital Management Company Limited, Innovation & Technology Fund Company, Hong Kong Science and Technology Parks, Investment Arm CI

Valuation

Fiscal Period: December 2020 2021 2023 2024 2025
Capitalization 1 5,194 6,117 11,268 28,375 -
Enterprise Value (EV) 1 5,194 6,117 11,268 28,116 27,421
P/E ratio - - -46.5 x -70.8 x 36.1 x
Yield - - - - -
Capitalization / Revenue 240 x 352 x - 437 x 18.1 x
EV / Revenue 240 x 352 x - 433 x 17.5 x
EV / EBITDA - - - -77.7 x 24.9 x
EV / FCF - -13.5 x - -75.8 x 57.4 x
FCF Yield - -7.4% - -1.32% 1.74%
Price to Book - 3.1 x - 28.4 x 15.9 x
Nbr of stocks (in thousands) 147,345 151,973 164,974 164,974 -
Reference price 2 35.25 40.25 68.30 172.0 172.0
Announcement Date 3/25/21 3/4/22 4/1/24 - -
1TWD in Million2TWD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2023 2024 2025
Net sales 1 21.65 17.36 - 65 1,570
EBITDA 1 - - - -362 1,102
EBIT 1 - -430.3 - -387 1,077
Operating Margin - -2,478.27% - -595.38% 68.6%
Earnings before Tax (EBT) 1 - - - -429 1,035
Net income 1 -322.6 - -238 -401 786
Net margin -1,489.83% - - -616.92% 50.06%
EPS 2 - - -1.470 -2.430 4.760
Free Cash Flow 1 - -452.7 - -371 478
FCF margin - -2,607.34% - -570.77% 30.45%
FCF Conversion (EBITDA) - - - - 43.38%
FCF Conversion (Net income) - - - - 60.81%
Dividend per Share - - - - -
Announcement Date 3/25/21 3/4/22 4/1/24 - -
1TWD in Million2TWD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 0.634 10.06 13 17 15 19
EBITDA 1 - - -89 -92 -91 -90
EBIT 1 -103.2 -149.8 -95 -98 -97 -96
Operating Margin -16,279.02% -1,488.23% -730.77% -576.47% -646.67% -505.26%
Earnings before Tax (EBT) 1 - - -108 -103 -110 -109
Net income 1 - - -101 -96 -103 -102
Net margin - - -776.92% -564.71% -686.67% -536.84%
EPS 2 - - -0.6100 -0.5800 -0.6200 -0.6200
Dividend per Share - - - - - -
Announcement Date 11/8/21 3/4/22 - - - -
1TWD in Million2TWD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2023 2024 2025
Net Debt 1 - - - - -
Net Cash position 1 - - - 259 954
Leverage (Debt/EBITDA) - - - - -
Free Cash Flow 1 - -453 - -371 478
ROE (net income / shareholders' equity) - 5.18% - -33.4% 56.4%
ROA (Net income/ Total Assets) - 4.64% - -27.8% 48.9%
Assets 1 - - - 1,442 1,607
Book Value Per Share 2 - 13.00 - 6.060 10.80
Cash Flow per Share 2 - - - -2.220 2.990
Capex 1 - 0.09 - 2 2
Capex / Sales - 0.5% - 3.08% 0.13%
Announcement Date 3/25/21 3/4/22 4/1/24 - -
1TWD in Million2TWD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
172 TWD
Average target price
2.28 TWD
Spread / Average Target
-98.67%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
LUMOSA THERAPEUTICS CO., LTD. Stock Lumosa Therapeutics Co., Ltd.
+151.83% 872M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.17% 104B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+2.87% 97.47B
ARGENX SE Stock argenx SE
+4.95% 22.25B
BIONTECH SE Stock BioNTech SE
-14.77% 21.68B
GENMAB A/S Stock Genmab A/S
-8.52% 18.2B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.98% 17.02B
BEIGENE, LTD. Stock BeiGene, Ltd.
-13.21% 16.36B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+8.55% 14.39B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+35.75% 12.37B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 6535 Stock
  4. Financials Lumosa Therapeutics Co., Ltd.